Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I,open label study to assess the safety and tolerability of ZD6474 [vandetanib] in combination with 5-fluorouracil, leucovorin [folinic acid] and oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal adenocarcinoma

Next Previous
Trial Profile

Phase I,open label study to assess the safety and tolerability of ZD6474 [vandetanib] in combination with 5-fluorouracil, leucovorin [folinic acid] and oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal adenocarcinoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandetanib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca

Most Recent Events

  • 24 Jan 2008 The expected completion date for this trial is now 1 Mar 2008.
  • 10 Aug 2007 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top